Abstract

HERNANDEZ-ROJAS, Edith C; ALMONACID URREGO, Isabel C; ROCHA CHAMORRO, Andrea Catalina  and  SALCEDO PRETELT, Irlena. COVID-19 vaccines: current status and perspectives for its development. Nova [online]. 2020, vol.18, n.spe35, pp.67-74.  Epub Jan 16, 2021. ISSN 1794-2470.  https://doi.org/10.22490/24629448.4188.

The SARS-CoV-2 pandemic shows the importance of joint work for the development of vaccines against the virus, these include complete viruses, subunits, attenuated vaccines, viral vectors and nucleic acids, most of the proposals are based on protein subunits. Of the more than 115 candidates reported until April, 73 are in preclinical studies, as of June the most advanced option is in phase II / II, one in phase II, two in phase I / II and four in phase I. The candidates more advanced are AZD1222 (AstraZeneca) based on recombinant adenovirus for protein S (phase II / III); PiCoVacc (Sinovac Biotech) based on inactivated virus (Phase I / II); while mRNA-1273 (Modern) based on mRNA for protein S, INO-4800 (Inovio Pharmaceticals) based on plasmid DNA for protein S, Ad5-nCoV (Cansino Biologicals) based on adenovirus type 5 expressing protein S, LV- SMENP-DC is based on dendritic cells with lentiviruses for viral protein domains and pathogen-specified aAPC, based on antigen-presenting cells with lentiviruses for viral protein domains (Shenzhen Institute of Genoimmune Medicine, are in phase I).

The purpose of this work against the clock is directed towards the sole objective of achieving a vaccine candidate who demonstrates safety and determination in the control and prevention of the surprising virus that revealed that there is no small enemy or that the smaller the more dangerous, because the cause of COVID-19 not only attacked human health but the economy of the planet and the customs and routine activities that humanity develops.

Keywords : COVID-19; Vaccines; SARS-CoV2; COVID-19 Control; Pandemic; Wuhan Coronavirus.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )